Truist analyst David MacDonald raised the firm’s price target on Pennant Group to $21 from $16 and keeps a Hold rating on the shares. The company reported “solid” Q4 results with the top-line ahead while adjusted EBITDA was roughly in-line on lower margins, the analyst tells investors in a research note. Total home health admissions were solid, hospice average daily census growth was strong and senior living occupancy grew y/y alongside strong revenue per unit growth, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PNTG:
- Pennant Group sees FY24 EPS 82c-91c, consensus 85c
- Pennant Group reports Q4 adjusted EPS 22c, consensus 22c
- Pennant Group Inc Unveils New Investor Presentation Online
- Pennant Reports Fourth Quarter and Fiscal Year 2023 Results
- Pennant Announces Fourth Quarter and Year-End 2023 Earnings Release and Call
